Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.

Miller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, Kolishetti N, Pittet M, Lippard SJ, Farokhzad OC, Weissleder R. · 2015

Read Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. by Miller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, Kolishetti N, Pittet M, Lippard SJ, Farokhzad OC, Weissleder R. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4711745.txt.

Introduction

Miles A. Miller, Yao-Rong Zheng, Suresh Gadde, and nine colleagues watched cancer nanomedicines at work inside tumors, in Nature Communications in 2015. Nanoparticles carrying platinum chemotherapy promise safer delivery, yet patient results have been erratic. Using single-cell imaging in living tumors, the team tracked both the particle and its platinum payload, plus the DNA damage each cell suffered. Their model particle used a fluorescent platinum pro-drug in a clinically tested polymer shell.

The surprise was the middleman. Tumor-associated macrophages, immune cells parked in the tumor, soaked up the particles and held them. Drug then leaked slowly from this macrophage depot into neighboring cancer cells. Removing the macrophages cut both particle buildup and treatment effect. The study reframes nanomedicine design: the macrophage reservoir is part of the delivery system, and patients whose tumors host many macrophages may benefit most from such drugs.

Catalog record

CREATORMiller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, Kolishetti N, Pittet M, Lippard SJ, Farokhzad OC, Weissleder R.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4711745

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug By Miles A. Miller, Yao-Rong Zheng, Suresh Gadde, Christina Pfirschke, Harshal Zope, Camilla Engblom, Rainer H. Kohler, Yoshiko Iwamoto, Katherine S. Yang, Bjorn Askevold, Nagesh Kolishetti, Mikael Pittet Published in: Nature Communications DOI: 10.1038/ncomms9692 ABSTRACT Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials. Approximately half of all cancer patients who receive chemotherapy are treated with one of three clinically approved platinum (Pt) drugs—cisplatin, carboplatin, and oxaliplatin1. These Pt compounds are first-line agents in ovarian, lung, head and neck and testicular cancers, among others, and development of combination therapies using Pt compounds is an active area of research2. Unfortunately, most cancers either exhibit intrinsic Pt resistance or ultimately develop resistance to treatment through mechanisms including reduced drug uptake, altered cellular metabolism, increased DNA repair, chemoprotective niche formation and/or activation of oncogenic and anti-apoptotic pathways3. Dose escalation and combination drug regimens help overcome resistance. However, Pt-related toxic side-effects including neurotoxicity and nephrotoxicity limit some of these approaches, indicating the need for new strategies. To circumvent these problems, specialized drug-delivery mechanisms such as nanoparticles (NPs) have been introduced to enhance local drug accumulation in tumours while simultaneously mitigating systemic toxicities45. Non-encapsulated Pt compounds in particular are often plagued by poor pharmacokinetic (PK) properties. They generally must be intravenously administered over a prolonged period (sometimes over 24 h) because promiscuous Pt reactivity causes side effects and the covalent binding to plasma proteins such as albumin consequently neutralizes its activity. Recent work has demonstrated the possibility of using NPs to encapsulate Pt pro-drugs, thereby (i) extending the circulating half-life of the unreacted Pt compound and enabling controlled drug release6; (ii) facilitating precisely engineered Pt-based combination therapies through co-encapsulation with additional drugs78 (or small interfering RNA treatments9); (iii) enabling the administration of more lipophilic and newer-generation Pt compounds10 and (iv) modifying tissue distribution and enhancing intratumoral accumulation69. The last is thought to occur through enhanced permeability and retention (EPR) effects and has been termed ‘passive NP targeting’11. In theory, enhanced permeability of the abnormal tumour microvasculature (TMV) should allow therapeutic nanoparticles (TNPs) to enter the tumour interstitial space, whereas suppressed lymphatic filtration and increased cellular uptake should allow them to stay there12. Although TNPs of Pt-based anticancer agents have advanced to clinical trials1314, results have been mixed, presumably due to heterogeneous EPR effects in different tumours combined with limited experimental data from patients on the effectiveness of this mechanism as related to enhanced drug accumulation15. Furthermore, the inter-related in vivo PK and pharmacodynamics (PD) of TNPs are more difficult to understand than those of the unencapsulated drug. TNP drug delivery is inherently a multi-step process, defined by PK of the TNP vehicle, drug release dynamics that may change depending on the in vivo environmental context, and PK of the Pt payload itself. Little experimental evidence exists that describes how this multi-step drug delivery sequence performs in vivo and within tumours, despite its critical importance to overall therapeutic outcome. This lack of understanding clearly represents a bottleneck in the design and development of more efficacious therapies. Here we use high-resolution microscopic imaging in live tumour-bearing mice to test the hypothesis that therapeutic nano-encapsulation not only affects traditional bulk PK properties, but also significantly influences heterogeneous drug uptake and response at the single-cell level within tumours1617. We engineer a platform that for the first time allows simultaneous imaging of both a ∼100-nm TNP vehicle as well as its Pt payload, in addition to monitoring DNA damage at the single-cell level in real time. As expected, our results show that nano-encapsulated Pt exhibits a longer circulating half-life than traditional unencapsulated Pt compounds. However, we quite unexpectedly find that TNPs accumulate at high levels within tumour-associated macrophages (TAMs), and that TAMs serve as ‘cellular drug reservoirs’. Indeed, TAMs release the Pt payload into neighbouring tumour cells over time. Depletion of macrophages significantly decreases intratumoral Pt accumulation and correspondingly increases tumour growth. Overall, this work establishes a paradigm for NP drug delivery based on the principle that TAMs can sequester TNP payload and gradually release it into the surrounding tissue, thereby serving as ‘drug depots.’ RESULTS Dual imaging shows congruent vehicle and payload kinetics For clinical applicability and generalizability, TNPs in this study were designed to incorporate desirable properties of previously described polymeric nano-formulations that have entered clinical trials5, especially those of materials that have received Food and Drug Adminstration approval. TNPs were formulated by combining three compounds (compounds 1–3, Fig. 1a) via nano-precipitation, using spectrally complementary derivatives of BODIPYs as ideal fluorophores for efficient nano-encapsulation that convey lipophilicity and robust in vivo imaging arising from in vivo structural stability, environmentally robust fluorescence, high brightness and high photostability16181920. Compound 3 (poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol); PLGA-b-PEG) self-assembles to form the hydrophobic PLGA core of the NP and hydrophilic PEG outer shell. For the cytotoxic payload, we used a novel Pt(IV) pro-drug (c,c,t-Pt(NH3)2Cl2-(hexadecylcarbamate)[4-((2-(4,4-difluoro-1,3,5,7-tetramethyl-4-dora-3a,4a-diaza-s-Indacene)ethyl)amino)-4-oxobutanoate]) with a C16 aliphatic carbon chain and a BODIPY (λex=498 nm, λem=543 nm; Supplementary Fig. 1a) as the two lipophilic ligands axially coordinated to the Pt(IV) centre. NPs were similar in size (135±1 nm; standard error of the mean (s.e.m.), across n=12; Supplementary Fig. 1b-c), polydispersity (PDI=0.18±0.01; s.e.m. across n=12) and drug release rates (t1/2 release=15 h; n=2; Supplementary Fig. 1d) compared with previously published Pt(IV) nano-formulations69, and were stable in physiological saline (Supplementary Fig. 1e). Free carboxylic acid terminal groups on the PEG gave TNPs a slight negative charge (zeta-potential=−23±1.4 mV; s.e.m. across n=4), which has been shown in some cases to benefit tumoral accumulation21222324 and mirrors TNPs in the clinic5. C16-Pt(IV) remains relatively stable in whole blood25. However, upon reduction to the active Pt(II) compound cisplatin, dissociated BODIPY increases fluorescence by sevenfold owing to loss of quenching by Pt(IV) (Supplementary Fig. 1f-g). BODIPY fluorescence thus serves as an effective indicator of both pro-drug delivery and activation. Overall, these properties enable clearly distinguishable imaging of both the TNP vehicle and its payload, in a stable and clinically relevant nano-formulation platform. We performed a series of in vitro experiments to characterize TNP behaviour in tumour cell culture (Supplementary Fig. 2a). Co-localization studies with fluorescent compartmentally localized proteins showed that the TNP vehicle moved from early to late endosomes over the course of 24 h (Supplementary Fig. 2b). Compared with the TNP vehicle, the TNP payload exhibited more diffuse intracellular localization, and co-localization peaked in the late endosome 24 h post treatment (Supplementary Fig. 2c). Payload fluorescence increased over time owing to Pt

Read the complete text